AAP
TLX

Arax Advisory Partners’s Telix Pharmaceuticals TLX Stock Holding History

Arax Advisory Partners’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.8K Buy
2,152
+2,027
+1,622% +$20.6K ﹤0.01% 3809
2026
Q1 		$9.86K Sell
125
-958
-88% -$7.3K ﹤0.01% 2448
2025
Q4 		$8.12K Buy
1,083
+53
+5% +$510 ﹤0.01% 2584
2025
Q3 		$9.86K Hold
1,030
– – ﹤0.01% 2608
2025
Q2 		$16.6K Buy
+1,030
New +$17.3K ﹤0.01% 1731

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Arax Advisory Partners's TLX Position: Q2 2026 in Review

Arax Advisory Partners increased its Telix Pharmaceuticals (TLX) stake by 1,622% in Q2 2026, buying an estimated $20.6K and bringing the position to 2,152 shares worth $24.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3809.

Arax Advisory Partners first reported a position in TLX in Q2 2025 and has held it in 5 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Arax Advisory Partners held 2,152 shares of Telix Pharmaceuticals worth $24.8K as of Q2 2026.
  • Arax Advisory Partners bought 2,027 Telix Pharmaceuticals shares in Q2 2026, an estimated $20.6K.
  • Telix Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3809 holding.
  • Arax Advisory Partners first reported a position in Telix Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.